Cesar Santa-Maria

Research output

Research output per year 2008 2015 2017 2018 2020 2022 2023 2024

• 47 Article
• 15 Review article
• 4 Comment/debate
• 2 Chapter
• 2 More
  • 2 Editorial

Research output per year

Research output per year

Search results

• 2024

  Atezolizumab in Combination with Carboplatin and Survival Outcomes in Patients with Metastatic Triple-Negative Breast Cancer: The TBCRC 043 Phase 2 Randomized Clinical Trial

  Lehmann, B. D., Abramson, V. G., Dees, E. C., Shah, P. D., Ballinger, T. J., Isaacs, C., Santa-Maria, C. A., An, H., Gonzalez-Ericsson, P. I., Sanders, M. E., Newsom, K. C., Abramson, R. G., Sheng, Q., Hsu, C. Y., Shyr, Y., Wolff, A. C. & Pietenpol, J. A., 2024, (Accepted/In press) In: JAMA Oncology.

  Research output: Contribution to journal › Article › peer-review

  Open Access

  • atezolizumab 100%
  • Triple Negative Breast Neoplasms 76%
  • Carboplatin 70%
  • Randomized Controlled Trials 42%
  • Survival 34%
• 2023

  Antibody-Drug Conjugates in Breast Cancer: Searching for Magic Bullets

  Santa-Maria, C. A. & Wolff, A. C., Feb 1 2023, In: Journal of Clinical Oncology. 41, 4, p. 732-735 4 p.

  Research output: Contribution to journal › Editorial › peer-review

  Open Access

• A Phase II Single-arm Study of Palbociclib in Patients With HER2-positive Breast Cancer With Brain Metastases and Analysis of ctDNA in Patients With Active Brain Metastases

  Shah, A. N., Santa-Maria, C. A., Mukhija, D., Shah, N., Kang, A. K., Kumthekar, P., Burdett, K., Chandra, S., Chang, J., Tsarwhas, D., Woodman, J., Jovanovic, B., Gerratana, L., Gradishar, W. & Cristofanilli, M., Apr 2023, In: Clinical Breast Cancer. 23, 3, p. 324-329 6 p.

  Research output: Contribution to journal › Article › peer-review

  • palbociclib 100%
  • Circulating Tumor DNA 90%
  • Brain Neoplasms 58%
  • Breast Neoplasms 39%
  • Neoplasm Metastasis 38%

• A transcriptome-informed QSP model of metastatic triple-negative breast cancer identifies predictive biomarkers for PD-1 inhibition

  Arulraj, T., Wang, H., Emens, L. A., Santa-Maria, C. A. & Popel, A. S., Jun 2023, In: Science Advances. 9, 26, eadg0289.

  Research output: Contribution to journal › Article › peer-review

  Open Access

  • Triple Negative Breast Neoplasms 100%
  • Transcriptome 76%
  • pembrolizumab 58%
  • Biomarkers 53%
  • Conservation of Natural Resources 28%

• Can breast MRI predict pathologic response following neoadjuvant chemotherapy for breast cancer? A retrospective cohort study

  Kwak, L., Santa-Maria, C., Di Carlo, P., Mullen, L. A., Myers, K., Oluyemi, E., Panigrahi, B., Rossi, J. & Ambinder, E. B., Sep 2023, In: Clinical Imaging. 101, p. 105-112 8 p.

  Research output: Contribution to journal › Article › peer-review

  • Breast 100%
  • Cohort Studies 89%
  • Retrospective Studies 88%
  • Magnetic Resonance Imaging 87%
  • Breast Neoplasms 83%

• Erratum: Uncovering the spatial landscape of molecular interactions within the tumor microenvironment through latent spaces (Cell Systems (2023) 14(4) (285–301.e4), (S2405471223000807), (10.1016/j.cels.2023.03.004))

  Deshpande, A., Loth, M., Sidiropoulos, D. N., Zhang, S., Yuan, L., Bell, A. T. F., Zhu, Q., Ho, W. J., Santa-Maria, C., Gilkes, D. M., Williams, S. R., Uytingco, C. R., Chew, J., Hartnett, A., Bent, Z. W., Favorov, S., Popel, A. S., Yarchoan, M., Kiemen, A., Wu, P. H., & 10 othersFujikura, K., Wirtz, D., Wood, L. D., Zheng, L., Jaffee, E. M., Anders, R. A., Danilova, L., Stein-O'Brien, G., Kagohara, L. T. & Fertig, E. J., Aug 16 2023, In: Cell Systems. 14, 8, p. 722 1 p.

  Research output: Contribution to journal › Comment/debate › peer-review

  Open Access

  • Confusion 100%
  • Tumor Microenvironment 94%
  • Emotions 71%

• Exceptional responses to PARP inhibitors in patients with metastatic breast cancer in oncologic crisis

  Cheng, J. M., Canzoniero, J., Lee, S., Soni, S., Mangini, N. & Santa-Maria, C. A., Jun 2023, In: Breast Cancer Research and Treatment. 199, 2, p. 389-397 9 p.

  Research output: Contribution to journal › Article › peer-review

  Open Access

  • Adenosine Diphosphate Ribose 100%
  • Breast Neoplasms 43%
  • Mutation 38%
  • Poly(ADP-ribose) Polymerase Inhibitors 25%
  • Neoplasms 15%

• Feasibility of Symptom Monitoring during the First Year of Endocrine Therapy for Early Breast Cancer Using Patient-Reported Outcomes Collected via Smartphone App

  Smith, K. L., Tsai, H. L., Lim, D., Wang, C., Nunes, R., Wilkinson, M. J., Sheng, J. Y., Couzi, R., Fetting, J., Riley, C., Wolff, A. C., Santa-Maria, C. A., Papathakis, K., Collins-Chase, L., Hilton, C., Thorner, E., Montanari, A., Ikejiani, D., Snyder, C. & Stearns, V., Nov 1 2023, In: JCO Oncology Practice. 19, 11, p. 981-989 9 p.

  Research output: Contribution to journal › Article › peer-review

  • Smartphone 100%
  • Patient Reported Outcome Measures 91%
  • cancer 75%
  • Breast Neoplasms 52%
  • electronics 32%

• Longitudinal Sedentary Time and Symptoms in Breast Cancer Patients during Chemotherapy Using Ecological Momentary Assessment

  Welch, W. A., Solk, P., Auster-Gussman, L., Whitaker, M., Siddique, J., Fanning, J., Mishory, A., Khan, S., Santa-Maria, C., Kulkarni, S. & Phillips, S. M., May 1 2023, In: Medicine and Science in Sports and Exercise. 55, 5, p. 966-974 9 p.

  Research output: Contribution to journal › Article › peer-review

  • Ecological Momentary Assessment 100%
  • Sedentary Behavior 77%
  • Breast Neoplasms 45%
  • Drug Therapy 42%
  • Anxiety 15%

• Optimizing and Refining Immunotherapy in Breast Cancer

  Santa-Maria, C. A., Apr 1 2023, In: JCO Oncology Practice. 19, 4, p. 190-191 2 p.

  Research output: Contribution to journal › Comment/debate › peer-review

• The PD-1- and LAG-3-targeting bispecific molecule tebotelimab in solid tumors and hematologic cancers: a phase 1 trial

  Luke, J. J., Patel, M. R., Blumenschein, G. R., Hamilton, E., Chmielowski, B., Ulahannan, S. V., Connolly, R. M., Santa-Maria, C. A., Wang, J., Bahadur, S. W., Weickhardt, A., Asch, A. S., Mallesara, G., Clingan, P., Dlugosz-Danecka, M., Tomaszewska-Kiecana, M., Pylypenko, H., Hamad, N., Kindler, H. L., Sumrow, B. J., & 10 othersKaminker, P., Chen, F. Z., Zhang, X., Shah, K., Smith, D. H., De Costa, A., Li, J., Li, H., Sun, J. & Moore, P. A., Nov 2023, In: Nature medicine. 29, 11, p. 2814-2824 11 p.

  Research output: Contribution to journal › Article › peer-review

  Open Access

  • Maximum Tolerated Dose 100%
  • margetuximab 58%
  • Safety 49%
  • Dose 44%
  • Refractory 30%

• Uncovering the spatial landscape of molecular interactions within the tumor microenvironment through latent spaces

  Deshpande, A., Loth, M., Sidiropoulos, D. N., Zhang, S., Yuan, L., Bell, A. T. F., Zhu, Q., Ho, W. J., Santa-Maria, C., Gilkes, D. M., Williams, S. R., Uytingco, C. R., Chew, J., Hartnett, A., Bent, Z. W., Favorov, A. V., Popel, A. S., Yarchoan, M., Kiemen, A., Wu, P. H., & 10 othersFujikura, K., Wirtz, D., Wood, L. D., Zheng, L., Jaffee, E. M., Anders, R. A., Danilova, L., Stein-O'Brien, G., Kagohara, L. T. & Fertig, E. J., Apr 19 2023, In: Cell Systems. 14, 4, p. 285-301.e4

  Research output: Contribution to journal › Article › peer-review

  Open Access

  • Tumor Microenvironment 100%
  • Cell Communication 60%
  • Small Cytoplasmic RNA 57%
  • Technology 41%
  • Spatial Analysis 41%
• 2022

  A randomized phase 2 study of neoadjuvant carboplatin and paclitaxel with or without atezolizumab in triple negative breast cancer (TNBC) - NCI 10013

  Ademuyiwa, F. O., Gao, F., Street, C. R., Chen, I., Northfelt, D. W., Wesolowski, R., Arora, M., Brufsky, A., Dees, E. C., Santa-Maria, C. A., Connolly, R. M., Force, J., Moreno-Aspitia, A., Herndon, J. M., Carmody, M., Davies, S. R., Larson, S., Pfaff, K. L., Jones, S. M., Weirather, J. L., & 6 othersGiobbie-Hurder, A., Rodig, S. J., Liu, Z., Hagemann, I. S., Sharon, E. & Gillanders, W. E., Dec 2022, In: npj Breast Cancer. 8, 1, 134.

  Research output: Contribution to journal › Article › peer-review

  Open Access

  • atezolizumab 100%
  • Triple Negative Breast Neoplasms 76%
  • Carboplatin 70%
  • Paclitaxel 63%
  • Tumor-Infiltrating Lymphocytes 21%

• Author Correction: Neoadjuvant study of niraparib in patients with HER2-negative, BRCA-mutated, resectable breast cancer (Nature Cancer, (2022), 10.1038/s43018-022-00400-2)

  Spring, L. M., Han, H., Liu, M. C., Hamilton, E., Irie, H., Santa-Maria, C. A., Reeves, J., Pan, P., Shan, M., Tang, Y., Graham, J. R., Hazard, S., Ellisen, L. W. & Isakoff, S. J., Sep 2022, In: Nature Cancer.

  Research output: Contribution to journal › Comment/debate › peer-review

  Open Access

  • niraparib 100%
  • Ovarian Neoplasms 49%
  • Reading 47%
  • Breast Neoplasms 34%
  • Neoplasms 17%

• Call for action: expanding global access to hereditary cancer genetic testing

  Bychkovsky, B., Rana, H. Q., Ademuyiwa, F., Plichta, J., Anderson, K., Nogueira-Rodrigues, A., Santa-Maria, C. A., Coffman, L. G., Marquez, C., Das, A., Taghian, A., Koeller, D. R., Sandoval, R. L., Park, B. H. & Dizon, D. S., Sep 2022, In: The Lancet Oncology. 23, 9, p. 1124-1126 3 p.

  Research output: Contribution to journal › Comment/debate › peer-review

• Dynamics of tumor-associated macrophages in a quantitative systems pharmacology model of immunotherapy in triple-negative breast cancer

  Wang, H., Zhao, C., Santa-Maria, C. A., Emens, L. & Popel, A. S., Aug 19 2022, In: iScience. 25, 8, 104702.

  Research output: Contribution to journal › Article › peer-review

  Open Access

  • Triple Negative Breast Neoplasms 100%
  • Immunotherapy 73%
  • Macrophages 58%
  • Pharmacology 55%
  • Tumor Microenvironment 34%

• Immunotherapy Combined with Radiation Therapy in Breast Cancer: A Rapidly Evolving Landscape

  Santa-Maria, C. A., Dunn, S. A. & Ho, A. Y., Jul 2022, In: Seminars in Radiation Oncology. 32, 3, p. 291-297 7 p.

  Research output: Contribution to journal › Review article › peer-review

  Open Access

  • Immunotherapy 100%
  • Radiotherapy 78%
  • Breast Neoplasms 72%
  • Combination Drug Therapy 22%
  • Apoptosis 13%

• Integrating Immunotherapy in Early-Stage Triple-Negative Breast Cancer: Practical Evidence-Based Considerations

  Santa-Maria, C. A., O’Donnell, M., Nunes, R., Wright, J. L. & Stearns, V., Jul 2022, In: JNCCN Journal of the National Comprehensive Cancer Network. 20, 7, p. 738-744 7 p.

  Research output: Contribution to journal › Article › peer-review

  Open Access

  • Triple Negative Breast Neoplasms 100%
  • Immunotherapy 73%
  • pembrolizumab 58%
  • Capecitabine 52%
  • Anthracyclines 47%

• Neoadjuvant study of niraparib in patients with HER2-negative, BRCA-mutated, resectable breast cancer

  Spring, L. M., Han, H., Liu, M. C., Hamilton, E., Irie, H., Santa-Maria, C. A., Reeves, J., Pan, P., Shan, M., Tang, Y., Graham, J. R., Hazard, S., Ellisen, L. W. & Isakoff, S. J., Aug 2022, In: Nature Cancer. 3, 8, p. 927-931 5 p.

  Research output: Contribution to journal › Article › peer-review

  Open Access

  • niraparib 100%
  • Breast Neoplasms 34%
  • Patient Safety 13%
  • Safety 7%
  • Neoplasms 4%

• Social cognitive variables and physical activity during chemotherapy for breast cancer: An intensive longitudinal examination

  Auster-Gussman, L. A., Gavin, K. L., Siddique, J., Welch, W. A., Solk, P., Whitaker, M., Cullather, E., Fanning, J., Maria, C. S., Gradishar, W., Khan, S., Kulkarni, S. & Phillips, S. M., Mar 2022, In: Psycho-Oncology. 31, 3, p. 425-435 11 p.

  Research output: Contribution to journal › Article › peer-review

  • cancer 100%
  • Exercise 71%
  • Breast Neoplasms 70%
  • Drug Therapy 64%
  • examination 63%

• The impact of weight loss on physical function and symptoms in overweight or obese breast cancer survivors: results from POWER-remote

  Sheng, J. Y., Santa-Maria, C. A., Blackford, A. L., Lim, D., Carpenter, A., Smith, K. L., Cohen, G. I., Coughlin, J., Appel, L. J., Stearns, V. & Snyder, C., Jun 2022, In: Journal of Cancer Survivorship. 16, 3, p. 542-551 10 p.

  Research output: Contribution to journal › Article › peer-review

  Open Access

  • Cancer Survivors 100%
  • Overweight 80%
  • Weight Loss 75%
  • Patient Reported Outcome Measures 67%
  • Breast Neoplasms 58%

• The tumor microenvironment and triple-negative breast cancer aggressiveness: shedding light on mechanisms and targeting

  Furukawa, N., Stearns, V., Santa-Maria, C. A. & Popel, A. S., 2022, In: Expert opinion on therapeutic targets. 26, 12, p. 1041-1056 16 p.

  Research output: Contribution to journal › Review article › peer-review

  • Triple Negative Breast Neoplasms 100%
  • Tumor Microenvironment 86%
  • Stromal Cells 18%
  • Expert Testimony 9%
  • Neoplasms 8%

• Using ecological momentary assessment to understand associations between daily physical activity and symptoms in breast cancer patients undergoing chemotherapy

  Whitaker, M., Welch, W. A., Fanning, J., Santa-Maria, C. A., Auster-Gussman, L. A., Solk, P., Khan, S. A., Kulkarni, S. A., Gradishar, W., Siddique, J. & Phillips, S. M., Aug 2022, In: Supportive Care in Cancer. 30, 8, p. 6613-6622 10 p.

  Research output: Contribution to journal › Article › peer-review

  • Ecological Momentary Assessment 100%
  • Exercise 46%
  • Breast Neoplasms 45%
  • Drug Therapy 42%
  • Light 25%
• 2021

  Editorial: Immunotherapy as an Evolving Approach for the Treatment of Breast Cancer

  Tolba, M. F., Santa-Maria, C. A., Albini, A., Chimusa, E. R., Al-Ramadi, B. K. & Tolaney, S. M., Nov 24 2021, In: Frontiers in Oncology. 11, 752689.

  Research output: Contribution to journal › Editorial › peer-review

  Open Access

• Factors affecting time to brain metastases for stage 2 and 3 breast cancer patients: A large single-institutional analysis with potential screening implications

  Cao, T. Q., Dixit, K., Santa-Maria, C. & Kumthekar, P., Jan 1 2021, In: Neuro-Oncology Advances. 3, 1, vdab009.

  Research output: Contribution to journal › Article › peer-review

  Open Access

  • Breast Cancer 3 100%
  • Neoplasm Metastasis 42%
  • Brain 33%
  • Breast Neoplasms 14%
  • Multivariate Analysis 10%

• Landmark trials in the medical oncology management of metastatic breast cancer

  Lu, P., Santa-Maria, C. A., Ballinger, T. J. & Sheng, J. Y., Jun 2021, In: Seminars in oncology. 48, 3, p. 246-258 13 p.

  Research output: Contribution to journal › Review article › peer-review

  Open Access

  • Medical Oncology 100%
  • Breast Neoplasms 53%
  • Survival 26%
  • pertuzumab 18%
  • Cyclin-Dependent Kinase 6 18%

• Pembrolizumab for patients with leptomeningeal metastasis from solid tumors: Efficacy, safety, and cerebrospinal fluid biomarkers

  Naidoo, J., Schreck, K. C., Fu, W., Hu, C., Carvajal-Gonzalez, A., Connolly, R. M., Santa-Maria, C. A., Lipson, E. J., Holdhoff, M., Forde, P. M., Douville, C., Riemer, J., Barnes, A., Redmond, K. J., Kleinberg, L., Page, B., Aygun, N., Kinzler, K. W., Papadopoulos, N., Bettegowda, C., & 3 othersVenkatesan, A., Brahmer, J. R. & Grossman, S. A., Aug 11 2021, In: Journal for immunotherapy of cancer. 9, 8, e002473.

  Research output: Contribution to journal › Article › peer-review

  Open Access

  • pembrolizumab 100%
  • Cerebrospinal Fluid 61%
  • Biomarkers 46%
  • Neoplasm Metastasis 43%
  • Safety 41%

• Relationship of circulating immune cells with lifestyle factors and cancer recurrence in early-stage breast cancer

  Xie, E., Lapinski, M. M., Talamantes, S., Nonyane, B. A. S., Magalhães, M. C. F., Visvanathan, K., Wolff, A. C. & Santa-Maria, C. A., Apr 2021, In: Breast Cancer Research and Treatment. 186, 2, p. 561-568 8 p.

  Research output: Contribution to journal › Article › peer-review

  • Life Style 100%
  • Breast Neoplasms 78%
  • Recurrence 70%
  • Monocytes 61%
  • Neoplasms 39%
• 2020

  Circulating immune cell dynamics in patients with triple negative breast cancer treated with neoadjuvant chemotherapy

  Talamantes, S., Xie, E., Costa, R. L. B., Chen, M., Rademaker, A. & Santa-Maria, C. A., Oct 1 2020, In: Cancer medicine. 9, 19, p. 6954-6960 7 p.

  Research output: Contribution to journal › Article › peer-review

  Open Access

  • Triple Negative Breast Neoplasms 100%
  • Monocytes 51%
  • Disease-Free Survival 48%
  • Drug Therapy 48%
  • Lymphopenia 25%

• Daily physical activity and symptom reporting in breast cancer patients undergoing chemotherapy: An intensive longitudinal examination

  Phillips, S. M., Welch, W. A., Fanning, J., Santa-Maria, C. A., Gavin, K. L., Auster-Gussman, L. A., Solk, P., Lu, M., Cullather, E., Khan, S. A., Kulkarni, S. A., Gradishar, W. & Siddique, J., Dec 2020, In: Cancer Epidemiology Biomarkers and Prevention. 29, 12, p. 2608-2616 9 p.

  Research output: Contribution to journal › Article › peer-review

  Open Access

  • Exercise 100%
  • Breast Neoplasms 98%
  • Drug Therapy 90%
  • Light 58%
  • Activities of Daily Living 23%

• Extended Endocrine Therapy for Early-Stage Breast Cancer: How Do We Decide?

  Walsh, E. M., Nunes, R., Wilkinson, M. J. & Santa-Maria, C. A., Dec 1 2020, In: Current oncology reports. 22, 12, 123.

  Research output: Contribution to journal › Review article › peer-review

  • Breast Neoplasms 100%
  • Recurrence 51%
  • Aromatase Inhibitors 27%
  • Therapeutics 25%
  • Patient Preference 24%

• Landmark trials in the medical oncology management of early stage breast cancer

  Hensing, W., Santa-Maria, C. A., Peterson, L. L. & Sheng, J. Y., Oct 2020, In: Seminars in oncology. 47, 5, p. 278-292 15 p.

  Research output: Contribution to journal › Review article › peer-review

  Open Access

  • Medical Oncology 100%
  • Breast Neoplasms 53%
  • Triple Negative Breast Neoplasms 33%
  • Standard of Care 27%
  • Early Detection of Cancer 26%
  1 Scopus citations

• Management of Breast Cancer during the COVID-19 Pandemic: A Stage-and Subtype-Specific Approach

  Sheng, J. Y., Santa-Maria, C. A., Mangini, N., Norman, H., Couzi, R., Nunes, R., Wilkinson, M., Visvanathan, K., Connolly, R. M., Torres, E. T. R., Fetting, J. H., Armstrong, D. K., Tao, J. J., Jacobs, L., Wright, J. L., Thorner, E. D., Hodgdon, C., Horn, S., Wolff, A. C., Stearns, V., & 1 othersSmith, K. L., Oct 1 2020, In: JCO Oncology Practice. 16, 10, p. 665-674 10 p.

  Research output: Contribution to journal › Article › peer-review

  Open Access

  • Pandemics 100%
  • cancer 85%
  • Breast Neoplasms 59%
  • management 44%
  • surgery 32%
  7 Scopus citations

• Optimizing Radiation Therapy to Boost Systemic Immune Responses in Breast Cancer: A Critical Review for Breast Radiation Oncologists

  Ho, A. Y., Wright, J. L., Blitzblau, R. C., Mutter, R. W., Duda, D. G., Norton, L., Bardia, A., Spring, L., Isakoff, S. J., Chen, J. H., Grassberger, C., Bellon, J. R., Beriwal, S., Khan, A. J., Speers, C., Dunn, S. A., Thompson, A., Santa-Maria, C. A., Krop, I. E., Mittendorf, E., & 2 othersKing, T. A. & Gupta, G. P., Sep 1 2020, In: International Journal of Radiation Oncology Biology Physics. 108, 1, p. 227-241 15 p.

  Research output: Contribution to journal › Review article › peer-review

  Open Access

  • Radiation Oncologists 100%
  • acceleration (physics) 83%
  • breast 79%
  • radiation therapy 75%
  • cancer 70%
  3 Scopus citations

• Patient-reported Outcomes of Patients With Breast Cancer During the COVID-19 Outbreak in the Epicenter of China: A Cross-sectional Survey Study

  Juanjuan, L., Santa-Maria, C. A., Hongfang, F., Lingcheng, W., Pengcheng, Z., Yuanbing, X., Yuyan, T., Zhongchun, L., Bo, D., Meng, L., Qingfeng, Y., Feng, Y., Yi, T., Shengrong, S., Xingrui, L. & Chuang, C., Oct 2020, In: Clinical Breast Cancer. 20, 5, p. e651-e662

  Research output: Contribution to journal › Article › peer-review

  Open Access

  • Coronavirus 100%
  • Patient Reported Outcome Measures 87%
  • Disease Outbreaks 70%
  • China 64%
  • Cross-Sectional Studies 51%
  22 Scopus citations

• Phase II study of pembrolizumab and capecitabine for triple negative and hormone receptor-positive, HER2-negative endocrine-refractory metastatic breast cancer

  Shah, A. N., Flaum, L., Helenowski, I., Santa-Maria, C. A., Jain, S., Rademaker, A., Nelson, V., Tsarwhas, D., Cristofanilli, M. & Gradishar, W., Feb 13 2020, In: Journal for immunotherapy of cancer. 8, 1, e000173.

  Research output: Contribution to journal › Article › peer-review

  Open Access

  • pembrolizumab 100%
  • Capecitabine 89%
  • Hormones 50%
  • Breast Neoplasms 45%
  • Progression-Free Survival 24%
  11 Scopus citations

• TBCRC 048: Phase II Study of Olaparib for Metastatic Breast Cancer and Mutations in Homologous Recombination-Related Genes

  Tung, N. M., Robson, M. E., Ventz, S., Santa-Maria, C. A., Nanda, R., Marcom, P. K., Shah, P. D., Ballinger, T. J., Yang, E. S., Vinayak, S., Melisko, M., Brufsky, A., DeMeo, M., Jenkins, C., Domchek, S., D’Andrea, A., Lin, N. U., Hughes, M. E., Carey, L. A., Wagle, N., & 5 othersWulf, G. M., Krop, I. E., Wolff, A. C., Winer, E. P. & Garber, J. E., Dec 20 2020, In: Journal of Clinical Oncology. 38, 36, p. 4274-4282 9 p.

  Research output: Contribution to journal › Article › peer-review

  • olaparib 100%
  • Homologous Recombination 73%
  • Breast Neoplasms 41%
  • Mutation 36%
  • Poly(ADP-ribose) Polymerase Inhibitors 28%
  23 Scopus citations

• The Effects of a remote-based weight loss program on adipocytokines, metabolic markers, and telomere length in breast cancer survivors: The POWER-remote trial

  Santa-Maria, C. A., Coughlin, J. W., Sharma, D., Armanios, M., Blackford, A. L., Schreyer, C., Dalcin, A., Carpenter, A., Jerome, G. J., Armstrong, D. K., Chaudhry, M., Cohen, G. I., Connolly, R. M., Fetting, J., Miller, R. S., Smith, K. L., Snyder, C., Wolfe, A., Wolff, A. C., Huang, C. Y., & 2 othersAppel, L. J. & Stearns, V., Jun 15 2020, In: Clinical Cancer Research. 26, 12, p. 3024-3034 11 p.

  Research output: Contribution to journal › Article › peer-review

  Open Access

  • Weight Reduction Programs 100%
  • Adipokines 84%
  • Telomere 81%
  • Cancer Survivors 81%
  • Weight Loss 60%
  3 Scopus citations
• 2019

  Feasibility and acceptability of intensive longitudinal data collection of activity and patient-reported outcomes during chemotherapy for breast cancer

  Solk, P., Gavin, K., Fanning, J., Welch, W., Lloyd, G., Cottrell, A., Nielsen, A., Santa Maria, C. A., Gradishar, W., Khan, S. A., Kulkarni, S., Siddique, J. & Phillips, S. M., Dec 1 2019, In: Quality of Life Research. 28, 12, p. 3333-3346 14 p.

  Research output: Contribution to journal › Article › peer-review

  • Ecological Momentary Assessment 100%
  • Patient Reported Outcome Measures 98%
  • cancer 81%
  • Breast Neoplasms 57%
  • Drug Therapy 52%
  6 Scopus citations

• In silico simulation of a clinical trial with anti-CTLA-4 and anti-PD-L1 immunotherapies in metastatic breast cancer using a systems pharmacology model

  Wang, H., Milberg, O., Bartelink, I. H., Vicini, P., Wang, B., Narwal, R., Roskos, L., Santa-Maria, C. A. & Popel, A. S., May 1 2019, In: Royal Society Open Science. 6, 5, 190366.

  Research output: Contribution to journal › Article › peer-review

  Open Access

  • Computer Simulation 100%
  • Immunotherapy 93%
  • Pharmacology 70%
  • Clinical Trials 69%
  • Breast Neoplasms 67%
  21 Scopus citations

• Relationship of pathological features and a 21 gene expression assay in younger versus older women with node-negative endocrine receptor-positive breast cancer

  Mutonga, M., Speedy, S., Rademaker, A., Liu, D., Uthe, R., Jain, S., Gradishar, W. J., Flaum, L. & Santa-Maria, C. A., Jul 15 2019, In: Breast Cancer Research and Treatment. 176, 1, p. 95-100 6 p.

  Research output: Contribution to journal › Article › peer-review

  • Breast Neoplasms 100%
  • Gene Expression 93%
  • Recurrence 89%
  • Adjuvant Chemotherapy 22%
  • Estrogen Receptors 20%
  3 Scopus citations

• Use of Everolimus and Trastuzumab in Addition to Endocrine Therapy in Hormone-Refractory Metastatic Breast Cancer

  Paplomata, E., Zelnak, A., Santa-Maria, C. A., Liu, Y., Gogineni, K., Li, X., Moreno, C. S., Chen, Z., Kaklamani, V. & O'Regan, R. M., Jun 2019, In: Clinical Breast Cancer. 19, 3, p. 188-196 9 p.

  Research output: Contribution to journal › Article › peer-review

  Open Access

  • Everolimus 100%
  • Trastuzumab 94%
  • Hormones 55%
  • Breast Neoplasms 50%
  • Progression-Free Survival 16%
  2 Scopus citations
• 2018

  Adjuvant and neoadjuvant systemic therapies for early-stage breast cancer

  Santa-Maria, C. A. & Gradishar, W. J., 2018, The Breast: Comprehensive Management of Benign and Malignant Diseases. Elsevier Inc., p. 752-762.e4

  Research output: Chapter in Book/Report/Conference proceeding › Chapter

  • Neoadjuvant Therapy 100%
  • Breast Neoplasms 55%
  • Hormones 27%
  • Gene Expression Profiling 19%
  • Adjuvant Chemotherapy 19%
  1 Scopus citations

• A phase II study evaluating the efficacy of zoledronic acid in prevention of aromatase inhibitor-associated musculoskeletal symptoms: the ZAP trial

  Santa-Maria, C. A., Bardia, A., Blackford, A. L., Snyder, C., Connolly, R. M., Fetting, J. H., Hayes, D. F., Jeter, S. C., Miller, R. S., Nguyen, A., Quinlan, K., Rosner, G. L., Slater, S., Storniolo, A. M., Wolff, A. C., Zorzi, J., Henry, N. L. & Stearns, V., Aug 1 2018, In: Breast Cancer Research and Treatment. 171, 1, p. 121-129 9 p.

  Research output: Contribution to journal › Article › peer-review

  Open Access

  • Zoledronic Acid 100%
  • Aromatase Inhibitors 94%
  • Letrozole 70%
  • exemestane 51%
  • Pharmacogenetics 38%
  4 Scopus citations

• A pilot study of durvalumab and tremelimumab and immunogenomic dynamics in metastatic breast cancer

  Santa-Maria, C. A., Kato, T., Park, J. H., Kiyotani, K., Rademaker, A., Shah, A. N., Gross, L., Blanco, L. Z., Jain, S., Flaum, L., Tellez, C., Stein, R., Uthe, R., Gradishar, W. J., Cristofanilli, M., Nakamura, Y. & Giles, F. J., Apr 10 2018, In: Oncotarget. 9, 27, p. 18985-18996 12 p.

  Research output: Contribution to journal › Article › peer-review

  Open Access

  • tremelimumab 100%
  • durvalumab 96%
  • Triple Negative Breast Neoplasms 67%
  • Breast Neoplasms 35%
  • T-Cell Antigen Receptor 22%
  31 Scopus citations

• Immune checkpoint inhibitor therapy in breast cancer

  Santa-Maria, C. A. & Nanda, R., Oct 1 2018, In: JNCCN Journal of the National Comprehensive Cancer Network. 16, 10, p. 1259-1268 10 p.

  Research output: Contribution to journal › Review article › peer-review

  • Breast Neoplasms 100%
  • Neoplasms 50%
  • Cold Temperature 35%
  • Immunotherapy 34%
  • Immune System 31%
  15 Scopus citations

• Obese breast cancer patients and survivors: Management considerations

  Sheng, J. Y., Sharma, D., Jerome, G. & Santa-Maria, C. A., 2018, In: ONCOLOGY (United States). 32, 8, p. 410-417 8 p.

  Research output: Contribution to journal › Article › peer-review

  • Cancer Survivors 100%
  • Breast Neoplasms 58%
  • Obesity 38%
  • Overweight 32%
  • Body Weight 26%
  13 Scopus citations

• Phase I study of alpelisib (BYL-719) and trastuzumab emtansine (T-DM1) in HER2-positive metastatic breast cancer (MBC) after trastuzumab and taxane therapy

  Jain, S., Shah, A. N., Santa-Maria, C. A., Siziopikou, K., Rademaker, A., Helenowski, I., Cristofanilli, M. & Gradishar, W. J., Sep 1 2018, In: Breast Cancer Research and Treatment. 171, 2, p. 371-381 11 p.

  Research output: Contribution to journal › Article › peer-review

  • Alpelisib 100%
  • Ado-Trastuzumab Emtansine 87%
  • taxane 68%
  • Trastuzumab 63%
  • Breast Neoplasms 33%
  41 Scopus citations

• Synchronous breast cancer and alveolar rhabdomyosarcoma bone marrow metastases

  Shah, A., Weber, J., Floerke, A., Blanco, L., Santa-Maria, C., Aguinik, M. & Bhole, S., Jun 2018, In: Radiology Case Reports. 13, 3, p. 680-684 5 p.

  Research output: Contribution to journal › Article › peer-review

  Open Access

  • Alveolar Rhabdomyosarcoma 100%
  • Rhabdomyosarcoma 59%
  • Bone Marrow 48%
  • Breast Neoplasms 42%
  • Neoplasm Metastasis 41%
• 2017

  A pilot study of cabergoline for the treatment of metastatic breast cancer

  Costa, R., Santa-Maria, C. A., Scholtens, D. M., Jain, S., Flaum, L., Gradishar, W. J., Clevenger, C. V. & Kaklamani, V. G., Oct 1 2017, In: Breast Cancer Research and Treatment. 165, 3, p. 585-592 8 p.

  Research output: Contribution to journal › Article › peer-review

  • Cabergoline 100%
  • Prolactin Receptors 57%
  • Breast Neoplasms 42%
  • Prolactin 39%
  • Neoplasms 17%
  5 Scopus citations